PT - JOURNAL ARTICLE AU - YUKA MASUDA AU - YOSHIKAZU KANANAZAWA AU - KUNIHIKO MATSUNO AU - DAISUKE KAKINUMA AU - NOBUYUKI SAKURAZAWA AU - FUMIHIKO ANDO AU - NOBUTOSHI HAGIWARA AU - TSUTOMU NOMURA AU - SHUNJI KATO AU - TOSHIRO YOSHIYUKI AU - HIOSHI YOSHIDA TI - Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab AID - 10.21873/anticanres.15634 DP - 2022 Mar 01 TA - Anticancer Research PG - 1599--1605 VI - 42 IP - 3 4099 - http://ar.iiarjournals.org/content/42/3/1599.short 4100 - http://ar.iiarjournals.org/content/42/3/1599.full SO - Anticancer Res2022 Mar 01; 42 AB - Background/Aim: The impact of clinical response to taxanes plus ramucirumab (RAM) on overall survival (OS) has not been clarified for advanced gastric cancer (AGC), although this type of therapy is already in use as second-line chemotherapy (CTx). This study aimed to investigate the prognostic impact of the clinical response to taxanes plus ramucirumab (RAM) for AGC patients. Patients and Methods: This study included AGC patients treated with paclitaxel (PTX) or nab-paclitaxel (nab-PTX) and RAM. A retrospective analysis of response and survival rates in consecutive medical records of patients was performed. Results: Forty-two patients were enrolled. Median progression-free survival and OS were 5.4 months [95% confidence interval (CI)=4.440-6.361] and 11.8 months (95% CI=8.648-15.019), respectively. In Cox-hazard multivariate analysis, peritoneal metastasis [hazard ratio (HR)=2.830; 95% CI=1.320-6.067; p=0.008], and disease control rate (HR=0.310; 95% CI=0.129-0.741; p=0.008) were independent factors. Conclusion: The response to taxanes plus RAM CTx had an impact on the survival of patients with AGC.